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Abstract: Keeping the potential synergy of biological activity of synthetic anomalous 
derivatives of deazapurines and L-ascorbic acid (L-AA) in mind, we have synthesized new 3-, 
7- and 9-deazapurine derivatives of L-ascorbic (1−4, 8−10, 13−15) and imino-L-ascorbic acid 
(5−7, 11, 12, 16−19). These novel compounds were evaluated for their cytostatic and antiviral 
activity in vitro against human malignant tumour cell line panel and normal murine fibroflasts 
(3T3). Among all evaluated compounds, 9-deazapurine derivative of L-AA (13) exerted the 
most potent inhibitory activity on the growth of CEM/0 cells (IC50 = 4.1 ± 1.8 μM) and strong 
antiproliferative effect against L1210/0 (IC50 = 4.4 ± 0.3 μM) while 9-deazapurine derivative 
of L-AA (15) showed the best cytostatic effect against HeLa cells (IC50 = 5.6 ± 1.3 μM) and 
prominent cytostatic effect on L1210/0 (IC50 = 4.5 ± 0.5). Furthermore, 9-deazapurine 
derivative disubstituted with two imino-L-AA moieties (18) showed the best cytostatic 
activity against L1210/0 tumour cells (IC50 = 4.4 ± 0.3 μM) and the most prominent 
antiproliferative effect against MiaPaCa-2 cells (IC50 = 5.7 ± 0.3 μM). All these compounds 
showed selective cytostatic effect on tumour cell lines in comparison with normal murine 
fibroblasts (3T3). When evaluating their antiviral activity, the 3-deazapurine derivative of L-
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AA (3) exhibited the most prominent antiviral effect against both laboratory-adapted strains 
of cytomegalovirus (CMV) (AD-169 and Davis) (EC50 = 8.94 μM) at the same level of 
inhibitory concentration as the well-known drug ganciclovir and without cytotoxic effect on 
normal human embryonal lung (HEL) cells.  
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1. Introduction 
 
Numerous nucleoside derivatives are being used in treatment of viral, tumoural as well 
as bacterial and other diseases. Purine nucleoside antiviral drugs carbovir, didanosine and its 
prodrug 2',3'-dideoxyadenosine are currently used in treatment of human immunodeficieny 
virus caused disease (AIDS),1 while acyclovir, gancyclovir, [1] pencyclovir [2] and (S)-9-
(2,3-dihydroxypropyl)adenine ((S)-DHPA) [3] are used as nucleoside antiherpetic drugs. 
Moreover, 6-mercaptopurine and thioguanine have been applied as antitumoural drugs, 
azathioprine as an immunosuppressive drug used in organ transplatation and cladiribine in 
treatment of systemic mastocytosis [1]. With a constant aim to synthesize better and selective 
substances, modifications in sugar moiety or its analogue replacement and alterations in 
nucleoside bases were investigated synthetically and biologically. Replacement of nitrogen 
atoms with carbon atoms of known synthetic and natural purine derivatives provided 
numerous deazapurine derivatives with diverse biological activity. Thus, 3-deazaadenosine is 
a potent inhibitor of S-adenosylhomocysteine hydrolase and an attractive target for the design 
of antiviral drugs that has shown significant activity against HSV-1, HIV and oncogenic DNA 
viruses [4]. In addition, the C-2 and C-3 halogenated 3-deazapurine derivatives have shown 
anti-HBV activity [5] and demonstrated a strong ability of substrating Mycobacterium 
Tuberculosis adenosine kinase [4]. 3-Deazaadenine derivatives of biologically active 
cyclopenthyl adenine drugs arysteromycine and neoplanocin A retained their strong antiviral 
activity against HSV-1, vaccinia virus and HL-23 C-type virus with lower cytotoxicity [6]. 
Removal of hydroxymethyl substituent from carbocyclic moiety of deazaneoplanocin A 
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resulted in synthesis of 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-3-deazaadenine 
(DHCDA) which has demonstrated even more selective activity against vaccinia virus [7]. 
Besides, 3-deaza-aristeromycin and its ”carbocyclically nude“ derivative 3-deaza-DHCaA, 
retained strong broad antiviral activity spectrum with lower cytotoxicity [8, 9]. 3-
Dezaguanosine has shown a wide spectrum of antiviral activity against DNA and RNA 
viruses as well as antitumoural activity against L1210 tumoural cell line and against a few 
murine adenocarcinoma cells [1]. Introduction of halogen substituent in C-3 position of 3-
deazaguanine derivatives resulted in prominent antitumour properties on L1210, P388 and 
CCRF-CEM and B16-F10 tumoural cell lines [5].  
C-5 substituted derivatives of naturally isolated antibiotic tubercidine (7-deaza-
adenosine, pyrrolo[2,3-d]pyrimidine) exhibited less cytotoxicity in relation to tubercidine. C-7 
fluorinated and C-2’ methylated derivatives of tubercidine have shown strong inhibition of 
NS5B, nonstructural hepatitis C (HCV) protein [10−12], while C-7 halogenated and acyclic 
C-7 halogenated derivatives have shown prominent activity against human cytomegalovirus 
(HCMV) and against HCV-1 [12]. Sangivamycine and toyocamycine, 7-deazapurine broad 
spectrum antibiotics, also inhibit HCMV, while sangivamycine also shows antiproliferative 
activity, but those antibiotics exhibit cytotoxic effects [12]. Acyclic derivatives of 
sangivamycine showed the same antiviral acivity against HSV-1 and HCMV viruses as drug 
gancyclovir, without cytotoxic effects. N-3 regioisomer of xylocidine (inhibitor of cyclin-
dependent kinases, Cdk) compound BMK-Y101 is also a selective inhibitor of Cdk7 and 
Cdk9 and furthermore it causes apoptosis in hepatocellular tumour cells with no cytotoxic 
effects. BMK-Y101 and its prodrug are preclinical candidates for treatment of hepatocellular 
carcinoma [12].  
Furthermore, C-2 fluorinated and C-7 methylated and benzylated derivatives of 9-
deazaadenosine (pyrrolo[3,2-d]pirimidine) have shown a broad spectrum of antitumoural 
activities with lower cytotoxicity in relation to 9-deazaadenosine [13]. 2',3'-Dideoxy-9-
deazaguanosine and its monophosphate prodrug exhibited antiproliferative activity against 
L1210, CCRF-CEM and B16-F10 tumoural cell lines in micromolar concentrations [14].  
Our research group has synthesized numerous nucleoside derivatives of L-ascorbic 
acid which have demonstated a broad spectrum of antiproliferative activity against LI210/0, 
Molt4/C8, HepG2, MCF-7, HeLa, MiaPaca-2 and CEM/0 tumoural cell lines, as well as 
antiviral activity against CMV, thymidine kinase varicella zoster virus (TK+ and TK- VZV) 
and CMV cells (Davids strain) in micromolar concentrations [15−19]. Alteration of sugar 
moiety in natural or synthetic nucleosides with L-ascorbic acid succeded from its antioxidant 
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properties [20] and also antitumoural properties of its stearate and palmitate derivatives which 
have demonstrated inhibition of proliferation of mouse glioma, human glioma (U-373), 
glioblastoma (T98G) and renal carcinoma cells [21−23]. 
These findings prompt us to synthesize new types of variously halogenated 3-
deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-
ascorbic acid (Fig. 1) with a primary aim to evaluate their antiviral and cytotoxic activity 
potency. 
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Figure 1. Structures of novel halogenated 3-, 7- and 9-deazapurine derivatives of L-ascorbic 
(1−4, 8−10 and 13−15) or imino-L-ascorbic acid (5−7, 11, 12 and 16−19). 
 
2. Results and discussion 
 
2.1. Chemistry 
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 3-Deazapurine derivatives of L-ascorbic acid (1−4) were prepared under modified 
Vorbrüggen reaction conditions (Scheme 1). 3-Deazapurine bases (A, B and C) were silylated 
with either 1,1,1,3,3,3-hexamethyldisilazane (HMDS) and catalytic amount of ammonium-
sulphate (2,6-difluoro-3-chloro-3-deazapurine, A or 6-chloro-3-deazapurine, B) or 
bis(trimethylsilyl)acetamide (BSA) (3-bromo-3-deazapurine, C). Condensation reaction in 
situ of silylated 3-deazapurine bases (A, B and C) and 5,6-di-O-acetyl-2,3-di-O-benzyl-L-
ascorbic acid (dAdBAA, synthesized as previously described [15]) with Friedel-Crafts 
catalyst, trimethylsilyltrifluoromethane sulphonate (TMSOTf) afforded the new 3-
deazapurine derivatives of L-ascorbic acid (1−4, Scheme 1) containing ethylenic spacer 
between two moieties. 2,6-Difluoro-3-chloro-3-deazapurine base (B) was synthesized in six 
steps as previously described by Liu, M.-C. et al. [5] while 3-bromo-3-deazapurine base (A) 
was synthesized by cyclization reaction of 3,4-diamino-5-bromopyridine with diethoxymethyl 
acetate (DEMA). 3-Bromo-3-deazapurine derivative of L-AA (1) was isolated as N-9 
regioisomer and as a mixture of Z and E isomers in the ratio 4 : 1, while reaction between 3-
deazapurine base B and dAdBAA resulted in two regioisomers, N-7 as a Z isomer (2) and N-9 
as a mixture of Z and E isomers (3) in the ratio 3 : 1. 6-Chloro-3-deazapurine derivative of L-
AA (4) was isolated as N-7 regioisomer in equal Z and E isomer amounts. Ammonolysis of 
compounds 1−3 in dioxane and methanol gave compounds 5−7, bearing hydroxy group at the 
C-4 of now imino-L-ascorbic acid (imino-L-AA). Addition of amino group on the ethylenic 
spacer and the opening of the lactone ring enabled formation of imino-L-ascorbic acid with 
hydroxy group as a substituent on the new C-4 chiral stereocenter. Also, substitution of the 
fluorine atom with amino group at the C-6 position of the 3-deazapurine base occurred in the 
synthesis of 3-deazapurine derivative of imino-L-AA (7). Compound 4 underwent 
debenzylation with boron-trichloride (1 M in dichloromethane) which yielded the compound 
8, 3-deazapurine derivative of L-AA with free hydroxy groups at the C-2 and C-3 positions of 
L-AA, as mixture of Z and E izomers in the ratio 10 : 1.  
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Scheme 1. Synthesis of novel halogenated 3-deazapurine derivatives of L-ascorbic (1−4, 8) or 
imino-L-ascorbic acid (5−7). Reagents and conditions: (i) a) HMDS/ (NH4)2SO4/ Ar/ reflux/ 
24 h or BSA/ reflux/ 1.5 h; b) TMSOTf/ C2H4Cl2 or CH3CN/ Ar/ 55−60 °C/ 24 h; (ii) 
NH4OH/ MeOH/ 1,4-dioxane/ 0 °C/ r. t./ 24 h; (iii) BCl3/ CH2Cl2/ Ar/ -78 °C/ r. t./ 24 h. 
 
 7-Bromo-7-deazapurine derivative of L-AA (9) was prepared in a similar manner as 
compounds 2−4. Condensation reaction of 7-deazapurine base D and dAdBAA in 
Vorbrüggen reaction conditions gave N-1 regioisomer of compound 9 (Z : E = 3 : 1) (Scheme 
2). 6-Chloro-7-iodo-7-deazapurine derivative of L-AA (10) was not isolated under 
Vorbrüggen conditions, but was successfully obtained via reaction under Mitsunobu reaction 
conditions. Reaction between 7-deazapurine base E and 6-hydroxy-2,3-di-O-benzyl-4,5-
didehydro-L-ascorbic acid (HdBAA) with triphenylphosphine (PPh3) and diethyl 
azodicarboxylate (DEAD) afforded compound 10, 6-chloro-7-iodo-7-deazapurine substituted 
with 4,5-didehydro-5,6-dideoxy-L-ascorbic acid at N-9 position in the isomer ratio Z : E = 9 : 
1 (Scheme 2). Ammonolysis of compounds 9 and 10 in similar procedures as for the synthesis 
of 3-deazapurine derivatives of imino-L-AA (5−7) gave 7-deazapurine derivatives of imino-L-
AA 11 and 12, bearing the amino group at the C-4 chiral position of the lactame moiety 
(Scheme 2). As opposed to the structure of analogue derivatives of deazapurines and imino-L-
  8 
AA described in this paper (5−7, 11 and 16−19) which contain ethyl spacer between 7-
deazapurine and lactame moieties, compound 12 contains ethylenic spacer between those two 
moieties with the double bond between C-5 and C-6 atoms.   
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Scheme 2. Synthesis of novel halogenated 7-deazapurine derivatives of L-ascorbic (9, 10) or 
imino-L-ascorbic acid (11, 12). Reagents and conditions: (i) a) HMDS/ (NH4)2SO4/ Ar/ reflux/ 
24 h; b) TMSOTf/ C2H4Cl2/ Ar/ 55−60 °C/ 24 h; (ii) DEAD/ PPh3/ THF/ Ar/ -50 − -40 °C/ 3 
h/ r. t./ 24 h/ 40 °C/ 24 h; (iii) NH4OH/ MeOH/ 1,4-dioxane/ 0 °C/ r. t./ 24 h. 
 
 9-Deazapurine derivatives of L-AA (13−15) were prepared under Mitsunobu reaction 
conditions, via similar synthetic method for obtaining 7-deazapurine derivative of L-AA (11) 
(Scheme 3). Reaction of 2,6-dimethoxy-9-deazapurine base (F) and HdBAA gave N-7 
regioisomer 13 in equal isomer ratio (Z : E = 1 : 1), while reaction of 9-deazahypoxanthine 
base (G) and HdBAA resulted in obtaining two condensated derivatives, 9-
deazahypoxanthine monosubstituted with 4,5-didehydro-5,6-dideoxy-L-ascorbic acid at 
position N-1 (Z-14) and 9-deazahypoxanthine disubstituted with L-AA (15) at positions N-1 
and N-7 (Z, Z’’ related to both double bonds in 15). Ammonolysis of compound 13 produced 
2,6-dimethoxy-9-deazapurine derivative of imino-L-AA (16) and analogue to that, 
ammonolysis of 14 gave 9-deazahypoxanthine derivative of imino-L-AA (17) (Scheme 3). 
When subdued to ammonia, disubstituted 9-deazahypoxanthine derivative of L-AA (15) 
yielded two derivatives of 9-deazahypoxanthine and imino-L-AA (18 and 19) that presumably 
are in diasteroisomeric relation (Scheme 3). 
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 Scheme 3. Synthesis of novel alkylated 9-deazapurine derivatives of L-ascorbic (13−15) or 
imino-L-ascorbic acid (16−19). Reagents and conditions: (i) DEAD/ PPh3/ THF/ Ar/ -50 − -40 
°C/ 3 h/ r. t./ 24 h/ 40 °C/ 24 h; (ii) NH4OH/ MeOH/ 1,4-dioxane/ 0 °C/ r. t./ 24 h. 
 
 
2.2. Structural and conformational properties  
 
Table 1. 1H NMR chemical shifts (δ/ppm)a and H−H coupling constants (J/Hz) of compounds 
1−19 (for numeration of atoms in molecular skeleton cf. Fig. 1).  
Comp. H-2' H-3' H-6' H-8' H-9' OCH2-2 OCH2-3 Ph OH-4 H-5 H-6 
 NH 
(imino-
L-AA) 
1 8.44 (s, 1H) - 
8.93 
(s, 1H) 
8.49 
(s, 1H) - 
5.14 
(s, 2H) 
5.30 
(s, 2H) 
7.24−7.50 
(m, 10H) - 
5.67 
(t, 3J = 
6.5, 1H) 
5.39 
(d, 3J = 
6.5, 2H) 
- 
2 - - - 8.54  (s, 1H) - 
5.15 
(s, 2H) 
5.30 
(s, 2H) 
7.28–7.44 
(m, 10H) - 
5.70 
(t, 3J = 
6.6, 1H) 
5.39 
(d, 3J = 
6.6, 2H) 
- 
(Z)-3 - - - 8.71 (s, 1H) - 
5.16 
(s, 2H) 
5.31 
(s, 2H) 
7.28–7.46 
(m, 10H) - 
5.70 
(t, 3J = 
7.0, 1H) 
5.25 
(d, 3J = 
7.0, 2H) 
- 
(E)-3 - - - 8.58 (s, 1H) - 
5.19 
(s, 2H) 
5.40 
(s, 2H) 
7.28–7.46 
(m, 10H) - 
6.01 
(t, 3J = 
7.5, 1H) 
5.32 
(d, 3J = 
7.5, 2H) 
- 
(Z)-4 
 
8.14* 
(d, 3J = 
5.5, 1H) 
/8.15* 
(d, 3J = 
5.5, 1H) 
7.70* 
(d, 3J = 
5.5, 1H) 
/7.72* 
(d, 3J = 
5.5, 1H) 
- 8.56 (s, 1H) - 
5.15 
(s, 2H) 
5.03 
(s, 2H) 
7.3−7.5 
(m, 10H) - 
5.67 
(t, 3J = 
6.5, 1H) 
5.40 
(d, 3J = 
6.5, 2H) 
- 
(E)-4 
8.14* 
(d, 3J = 
5.5, 1H) 
/8.15* 
7.70* 
(d, 3J = 
5.5, 1H) 
/7.72* 
- 8.43 (s, 1H) - 
5.21 
(s, 2H) 
5.40 
(s, 2H) 
7.3−7.5 
(m, 10H) - 
5.97 
(t, 3J = 
7.2, 1H) 
5.47 
(d, 3J = 
7.2, 2H) 
- 
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(d, 3J = 
5.5, 1H) 
(d, 3J = 
5.5, 1H) 
5 
8.12 
(d, 3J = 
5.5, 1H) 
7.69 
(d, 3J = 
5.5, 1H) 
- 8.39 (s, 1H) - 
5.00 
(d, 2J = 
11.2, 1H), 
5.06 
(d, 2J = 
11.2, 1H) 
5.01 
(d, 2J = 
12.0, 1H), 
5.14 
(d, 2J = 
12.0, 1H) 
7.2−7.4 
(m, 10H) 
6.26 
(s, 1H) 
2.22 
(t, 3J = 
7.6, 2H) 
4.45 (m, 
2H) 
8.28 
(s, 1H) 
6 8.42 (s, 1H) - 
8.91 
(s, 1H) 
8.30 
(s, 1H) - 
5.00 
(d, 2J = 
11.1, 1H), 
5.07 
(d, 2J = 
11.1, 1H) 
5.02 
(d, 2J = 
12.0, 1H), 
5.13  
(d, 2J = 
12.0, 1H) 
7.18−7.50 
(m, 10H) 
6.30 
(s, 1H) 
2.22 
(t, 3J = 
7.4, 2H) 
4.43 
(m, 2H) 
8.27  
(s, 1H) 
7b - - - 7.92 (s, 1H) - 
5.00 
(d, 2J = 
11.2, 1H), 
5.06 
(d, 2J = 
11.2, 1H) 
5.00 
(d, 2J = 
11.8, 1H), 
5.13  
(d, 2J = 
11.8, 1H) 
7.22–7.43 
(m, 10H) 
6.25 
(s, 1H) 
2.18 
(t, 3J = 
7.5, 2H) 
4.30 
(m, 2H) 
8.25  
(s, 1H) 
8 - - - 8.74 (s, 1H) - - - - - 
5.54 
(t, 3J = 
7.2, 1H) 
5.22 
(d, 3J = 
7.2, 2H) 
- 
(Z)-9 
 
8.74 
(d, 2J = 
1.9, 1H) 
- 
8.92 
(d, 2J = 
1.9, 
1H) 
7.31−7.
47 (m, 
11H)c 
- 5.16 (s, 2H) 
5.31 
(s, 2H) 
7.31−7.47 
(m, 11H)c - 
5.85 
(t, 3J = 
7.1, 1H) 
5.27 
(d, 2J = 
7.1, 2H) 
- 
10 8.73 (s, 1H) - - 
8.50 
(s, 1H) - 
5.04 
(s, 2H) 
5.31 
(s, 2H) 
7.22−7.42 
(m, 10H) - 
6.68− 
6.72 
(m, 1H) 
4.83 
(d, 2J = 
6.0, 2H) 
- 
11 8.75 (m, 1H) - 
8.94 
(m, 1H) 
7.2−7.5 
(m, 
11H)c 
- 4.99 (s, 2H) 
5.02 
(d, 2J = 
11.9, 1H), 
5.11 
(d, 2J = 
11.9, 1H) 
7.2−7.5 
(m, 11H)c 
6.25 
(s, 1H) 
2.21 (m, 
1H), 
2.40 
(m, 1H) 
4.44 (m, 
2H) 
8.30 
(s, 1H) 
(E)-12 8.73  (s, 1H) - - 
8.50 
(s, 1H) - 
5.01 
(s, 2H) 
5.15 
(d, 2J = 
12.2, 1H), 
5.19 
(d, 2J = 
12.2, 1H) 
7.25−7.45 
(m, 10H) 
6.72 
(d, 4J 
= 0.7, 
1H) 
6.40 
(dd, 3J = 
14.3, 4J 
= 0.7, 
1H) 
7.62 
(d, 3J = 
14.3, 
1H) 
8.46  
(s, 1H) 
(Z)-
13d 
 
- - - 
7.58  
(d, 3J = 
3.0, 
1H) 
6.34 
(d,  3J 
= 3.0 
1H) 
5.16 (s, 
2H) 
5.29 (s, 
2H) 
7.22−7.50 
(m, 10H) - 
5.47 
(t, 3J = 
7.4, 1H) 
5.10 
(d,  3J = 
7.4, 2H) 
- 
(Z)-
14e 
8.10  
(s, 1H) - - 
7.38 
(m, 1H) 
6.37 
(dd, 3J 
= 2.7, 
1.9,  
1H) 
5.14 
(s, 2H) 
5.29  
(s, 2H) 
7.25−7.45 
(m, 10H) - 
5.54 
(t, 3J = 
6.9, 1H) 
4.82  
(d, 3J = 
6.9, 2H) 
- 
16f - - - 
7.41  
(d, 3J = 
3.0, 
1H) 
6.31 
(d, 3J = 
3.0, 
1H) 
4.97  
(s, 2H) 
4.94 
(d, 2J = 
11.9, 1H), 
5.11 
(d, 2J = 
11.9, 1H) 
7.20−7.40 
(m, 10H) 
6.17 
(s, 1H) 
2.12 (m, 
2H) 
4.16 
(t, 2H), 
3J = 7.5 
8.18  
(s, 1H) 
17g 7.93  (s, 1H) - - 
7.37 
(m, 1H) 
6.36 
(d, 3J = 
2.3, 
1H) 
5.02  
(s, 2H) 
5.01  
(d, 2J = 
11.8, 1H), 
5.13  
(d, 2J = 
11.8, 1H) 
7.20−7.45 
(m, 10H) 
6.16 
(s, 1H) 
2.08 (m, 
2H) 
3.95 (m, 
2H) 
8.23 
(s, 1H) 
Comp. H-2' H-3' H-6' H-8' H-9' OCH2-2 /OCH2-2'' 
OCH2-3 
/OCH2-3'' 
Ph/ Ph'' OH-4/ OH-4'' 
H-5/ 
H-5'' 
H-6/ 
H-6'' 
 NH/ 
NH’’ 
(imino-
L-AA) 
(Z, 
Z'')-15 
8.10  
(s, 1H) - - 
7.46  
(d, 3J = 
3.0, 
1H) 
6.36 
(d, 3J = 
3.0, 
1H) 
5.13 
(s, 2H), 
5.14 
(s, 2H)* 
/ 5.13 (s, 
2H), 
5.29 
(s, 2H)/ 
5.29 
(s, 2H) 
7.2-7.5 
(m, 10H)/ 
7.2−7.5 
(m, 10H) 
- 
5.56 
(t, 3J = 
7.1, 1H), 
/ 5.53 
(t, 3J = 
6.8, 1H) 
5.24 
(d, 3J = 
7.1, 2H), 
/ 4.79 
(d, 3J = 
6.8, 2H) 
- 
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5.14 
(s, 2H)* 
18 7.91 (s, 1H) - - 
7.26  
(d, 3J = 
2.9, 
1H) 
6.30 
(d, 3J = 
2.9, 
1H) 
5.01 
(s, 2H)/ 
5.01 
(s, 2H) 
4.95− 
5.15 (m, 
2H) 
/4.95− 
5.15 (m, 
2H) 
7.20−7.40 
(m, 10H)/ 
7.20−7.40 
(m, 10H) 
6.15 
(s, 
1H)/ 
6.17 
(s, 1H) 
2.18 
(m, 2H)/ 
2.07 
(m, 2H) 
4.31 
(m, 2H)/ 
3.92 
(t, 3J = 
7.2, 2H) 
8.15 
(s, 1H)/ 
8.24 
(s, 1H) 
19 7.91 (s, 1H) - - 
7.27  
(d, 3J = 
2.9, 
1H) 
6.30 
(d, 3J = 
2.9, 
1H) 
5.01 
(s, 2H)/ 
5.01 
(s, 2H) 
4.95− 
5.20 
(m, 2H) 
/ 4.95− 
5.20 
(m, 2H) 
7.20−7.50 
(m, 10H)/ 
7.20−7.50 
(m, 10H) 
6.14 
(s, 
1H)/ 
6.16 
(s, 1H) 
2.17 
(m, 2H)/ 
2.07 
(m, 2H) 
4.31 (m, 
2H)/ 
3.91 
(t, 3J = 
7.3, 2H) 
8.15 
(s, 1H)/ 
8.24 
(s, 1H) 
a 1H NMR chemical shifts are determined in reference to chemichal shift of the solvent DMSO-d6, δ (DMSO) = 
2.50 ppm. b δ (NH2-6') = 6.84 ppm (s, 2H). c Chemical shifts of H-8’ in 9 and 11 are overlapped with phenyl 
protons in the range δ 7.2−7.5 ppm (11 H). d δ (OCH3-2') = 3.84 (s, 3H), δ (OCH3-2') =  3.94 (s, 3H). e δ (NH-7') 
= 12.11 (s, 1H). f δ (OCH3-2') = 3.83 (s, 3H), δ (OCH3-2') = 3.91 (s, 3H). g δ (NH-7') = 12.10 (s, 1H). * Chemical 
shifts could not be unequivocally assigned. 
 
The chemical identities of deazapurine derivatives of L-ascorbic acid (1−4, 8−10, 
13−15) and imino-L-ascorbic acid (5−7, 11, 12, 16−19) were confirmed by 1H, 13C, 15N, 19F 
and 2D NMR measurements, as well as mass spectrometry spectra analysis (HPLC/MS/MS 
and MALDI-TOF/TOF). NMR chemical shifts are reported in Table 1 (1H), Experimental 
section (13C) and Supplementary (19F and 15N). 1H decoupled 13C NMR spectra showed C–F 
coupling constants that enabled straightforward identification of fluorinated carbon atoms and 
their neighbors. Notably, C-4’ and C-5’ displayed different multiplicity pattern due to the 
long-range coupling constants with two fluorine atoms in 2 and 3; C-4’ is coupled to both 
fluorine atoms over three bonds (3J = 4–12 Hz), whereas C-5’ showed coupling constants 
over two (2J = 27–34 Hz) and four bonds (4J = 3–4 Hz). Furthermore, 2D 19F-13C NMR 
spectra allowed unambiguous assignment of C-2’ and C-6’ in difluorinated deazapurines 2 
and 3 (Figure 2). 
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Figure 2. 19F-13C HSQC NMR spectrum of 2 in DMSO-d6 showed correlation signals for 
fluorine and carbon atoms coupled across a single bond. 
  
N-7’ and N-9’ regioisomers 2 and 3 were distinguished on the basis of heteronuclear 
1H–13C and 1H-15N correlation signals in 2D HMBC spectra. H-6 methylene protons in 2 (δ 
5.39 ppm) showed correlation signal with C-4’ (δ 141.67 ppm), which suggested that benzyl-
protected ascorbic acid is attached to N-9’ position of deazapurine scaffold. 15N chemical 
shifts of N-7’ and N-9’ in deazapurine 2 were observed at δ 240 and 163 ppm, respectively. In 
contrast, perusal of 2D NMR spectra of 3 showed correlation signal between H-6 methylene 
protons (δ 5.25 ppm) and C-5’ (δ 116.37 ppm) that indicated reaction proceeded at N-7’ 
position of deazapurine moiety. 15N chemical shifts in deazapurine 3 corroborated that 
ascorbic acid is attached at N-7’ position. N-7’ and N-9’ were observed at δ 158 and 243 ppm, 
respectively. Distinct shielding of C-4’ and C-5’ as well as N-7’ and N-9’ atoms in 
regioisomeric pair of 2/3 facilitated the assessment of structural features of the remaining 
regioisomers (Figure 3). 
 
 
Figure 3. The characteristic 15N chemical shifts for N-9’ (a) and N-7’ regioisomers (b) in 
compounds 1-6. 
 
Vicinal coupling constant 3JH5H6 = 14.3 Hz suggested E-configuration along C4=C5 
double bond in compound 12. Some NMR spectra exhibited two sets of signals, which were 
attributed to Z- and E-isomers. The configurations along C4=C5 double bond in 1-4 and 13-
15 were evaluated through long-range 3JC13H11 coupling constants, which were determined by 
J-HMBC NMR experiments. Small values between 2 and 3 Hz are in agreement with Z-
configuration along C4=C5 double bond, whereas 3JC13H11 between 7 and 8 Hz correspond to 
  13 
E-isomers (Table 2). Conformational study of compounds 2 and 4 showed only trivial 
NOESY cross-peaks. Consequently, no particular conformational preferences could be 
established for these compounds. 
 
Table 2.  1H-13C coupling constants (JC3H5, JC3''H5''/ Hz) and isomer ratio (Z : E) for 
compounds 1−4 and 13−15. 
 
1 2 3 4 13 14 15 
Z Z Z E Z E Z Z Z, Z'' 
J 2.0 2.5 2.6 7.3 2.0 7.0 2.0 3.0 3.0, 3.0 
Isomer ratio 
(Z : E) 
4 : 1 9.5 : 0.5 3 : 1 1 : 1 7 : 1 9.5 : 0.5 - 
 
 
2.3. Biological results 
 
2.3.1. Cytostatic activity 
 
Newly synthesized 3-, 7- and 9-deazapurine derivatives of L-ascorbic (1−4, 8−10, and 
13−15) and imino-L-ascorbic acid (5−7, 12 and 16−19) have been evaluated in vitro for their 
cytostatic effects on malignant human tumour cell lines including cervical carcinoma (HeLa), 
colorectal adenocarcinoma (SW620), murine leukemia (L1210/0), acute lymphoblastic 
leukemia (CEM/0), pancreatic carcinoma (MiaPaCa-2) and hepatocellular carcinoma 
(HepG2) (compound 9 tested at pancreatic adenocarcinoma cells, CFPAC-1) as well as their 
cytotoxic effects on mouse embryonic fibroblasts (3T3) (Table 2).  
Among tested compounds that exhibited the most prominent antitumour activities, 
only compounds 1 and 19 showed low cytotoxic effects on fibroblasts 3T3 (Table 2). Several 
deazapurine derivatives of L-AA and imino-L-AA expressed antiproliferative activity against 
L1210/0 cell lines in the micromolar concentration range: 3-bromo-3-deazapurine derivative 
of L-AA (1) (IC50 = 6.8 ± 0.1 μM), 2,6-dimethoxy-9-deazapurine derivative of L-AA (13) 
(IC50 = 4.7 ± 0.1 μM) and 9-deazahypoxanthine derivatives (15, 18, 19) (IC50 = 4.5 ± 0.5; 4.4 
± 0.3 and 7.6 ± 3.8 μM, respectively). Compounds 13, 15 and 18 were not cytotoxic for 3T3 
cells. 3-Deazapurine derivative of L-AA (1), as well as 9-deazapurine derivatives of L-AA 
(13) and imino-L-AA (19) have shown the most pronounced antitumoural activity against 
CEM/0 cell lines (IC50 = 5.7 ± 1.4 μM; 4.1 ± 1.8; 4.9 ± 0.3 μM, respectively) while amongst 
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them, only 2,6-dimethoxy-9-deazapurine derivative of L-AA (13) has not exhibited cytotoxic 
effect on fibroblasts 3T3. N-1 regioisomers of 7-bromo-7-deazapurine derivative of L-AA (9) 
and 9-deazahypoxanthine derivative of L-AA (14) have shown moderate antitumoural effects 
against L1210/0 (IC50 = 15 ± 0; 28 ± 5 μM, respectively) and against CEM/0 cell lines (IC50 = 
12 ± 0; 16 ± 2 μM, respectively) without cytotoxic effect on 3T3 cells (Supplementary data 
3). 9-Deazahypoxanthine derivative disubstituted with L-AA (15) has exhibited marked 
cytostatic effect against HeLa cell lines with IC50 value of 5.6 ± 1.3 μM without cytotoxic 
effects on mouse embryonic fibroblasts. 3-deazapurine derivative of L-AA (1), 7-deazapurine 
derivative of L-AA (9) and 9-deazapurine derivatives of L-AA (13) and imino-L-AA (18, 19) 
expressed moderate antitumoural activity against HeLa cells where compounds 13 and 18 
exerted no cytotoxic effects on 3T3 cells.  
Compounds 1, 6, 12, 16 and 19 have exerted weak and nonselective antiproliferative 
activity against all tested malignant cell lines and moderate or low cytotoxic effects on 3T3 
cells (Supplementary data 3), while amongst them, 3-bromo-3-deazapurine derivative of L-
AA (1) exhibited moderate activity against HeLa cells.  
 9-Deazapurine derivatives of L-AA (13) and imino-L-AA derivatives (15 and 18) 
which have exhibited the most prominent antitumoural activities will serve as model 
molecules for developing more selective and more active antitumoural substrates in this class 
of compounds. 
 
Table 3. Inhibitory effects of selected 3- and 9-deazapurine derivatives of L-ascorbic (1, 3, 13 
and 15) or imino-L-ascorbic acid (17−19) on the growth of malignant cell lines as well as their 
cytotoxic effects on normal diploid human fibroblasts (BJ) and murine fibroblasts (3T3). 
Comp. 
IC50a 
HeLa SW620 L1210/0 CEM/0 
MiaPaCa
-2 
HepG2 3T3 
1
O O
BnO OBn
N N
N
Br
(Z) : (E) = 4 : 1  
15 ± 0 32.9 ± 0.1 6.8 ± 0.1 5.7 ± 1.4 22.6 ± 0.1 46.9 ± 0.4 26.4 ± 0.1 
N
N
N
O O
BnO OBn
OCH3
H3CO
13
(Z) : (E) = 7 : 1  
12 ± 4 47.1 ± 0.1 4.7 ± 0.1 4.1 ± 1.8 33.9± 0.1 >100 >100 
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N
N
N
O O O
O
O OBn
BnO
OBn
BnO
(Z, Z'')-15  
5.6 ± 1.3 47.2 ± 0.1  4.5 ± 0.5 19 ± 12 26.2 ± 0.1 >100 >100 
H
N O
BnO OBn
HO
N
N
N
OCH3
H3CO
17  
92 ± 3 90.7 ± 0.1 107 ± 6 87 ± 0 36.6 ± 0.1 >100 >100 
N
N
N
O
HN
O
NH
O
OBn
BnO
OBn
BnO OH
HO
18  
17 ± 2 69.9  ± 0.1 4.4 ± 0.3 15 ± 4 5.7  ± 0.2 >100 >100 
N
N
N
O
HN
O
NH
O
OBn
BnO
OBn
BnO OH
HO
19  
18 ± 2 30.5  ± 0.1 7.6 ± 3.8 4.9 ± 0.3 4.4 ± 0.1 52 ± 0.1 63.5 ± 0.1 
a Inhibitory concentration (IC50) on tumour and normal fibroblast cell growth. b Not determined.  
 
2.3.2. Antiviral activity  
 
 Newly synthesized 3-, 7- and 9-deazapurine derivatives of L-ascorbic (1−4, 8−10, 
13−15) and imino-L-ascorbic acid (5−7, 12, 16−19) have been evaluated in vitro on human, 
monkey, feline and canine cells infected with numerous pathogenic viruses: human 
imunodeficency virus type 1 and 2 (HIV-1, HIV-2) in human T-lymphocyte cells (CEM); 
cytomegalovirus (CMV), Varicella-zoster virus (VZV), herpes simplex virus type 1 and 2 
(HSV-1 i 2), vaccinia virus (VV), vesicular stomatitis virus (VSV) and adenovirus-2 in 
human embryonic HEL cells; vesicular stomatitis, Coxsackie B4 and respitory syncitial virus 
in human HeLa cells; para-influenza, reovirus-1, Sindibis virus, Coxsackie B4, Punta Toro 
virus in Vero cells (african green monkey cells); feline Corona virus (feline infectious 
Peritonitis virus, FIVP) and herpes virus in Crandell-Rees feline kidney cells (CRFK); 
influenza A, subtype H1N1 and influenza B subtype H3N2 in Madin Darby canine kidney 
cell lines (MDCK). 
Amongst tested compounds (2−5, 7−8) against CMV replication, 2,6-difluoro-3-chloro-3-
deazapurine derivative of L-ascorbic acid (3) has exhibited the most prominent antiviral effect 
against this virus with EC50 value of 8.94 μM against both of the tested virus strains (AD-169 
and Davis) in the same level of inhibitory concentration as the drug ganciclovir and without 
cytotoxic effect on normal human embryonal lung (HEL) cells. Removal of benzyl protection 
groups of C-2 and C-3 hydroxyl groups of L-AA moiety in compound 8 resulted in loss of 
anti-CMV activity as well as in imino-L-AA analogue derivative 7, in comparison to the most 
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active compound 3. 2,6-Dimethoxy-9-deazapurine derivative of L-AA (13) has exhibited even 
lower EC50 values against these cell strains (EC50 = 1.79 μM) but also cytotoxic effect in HEL 
cells (CC50 =  15.4 μM). 
9-Deazahypoxanthine derivative substituted with two L-AA moieties (15) exerted very 
weak activity against both strains of VZV (TK+ and TK-) (EC50 = 13.8; 7.6 μM) with 
cytotoxic effect on HEL cells (CC50 = 20.0 μM). 
2,6-Difluoro-3-chloro-3-deazapurine derivatives of L-AA substituted at N-9 position of 
deazapurine moiety (2) and N-7 position (3) have exhibited the same value of effective 
concentration against Punta Toro virus (EC50 = 12 μM), but with strong cytostatic effect on 
human uninfected Vero cells (2: MCC ≥ 20 μM; 3: MCC = 20 μM). Besides that, compound 2 
has also shown moderate antiviral activity against Coxsackie B4 virus in Vero cells with EC50 
value of 14.5 μM, while when tested on HeLa cells infected with the same virus, it did not 
exhibited any antiviral activity (EC50 > 100 μM).   
9-Deazahypoxanthine derivative disubstituted with two L-AA moieties at N-1 and N-7 
positions (15) exhibited even stronger antiviral activity against Punta Toro virus (EC50 = 4.5; 
8.9 μM) in accordance to EC50 concentrations of compounds 2 and 3 against the same virus. 
In comparison with antiviral activity of drugs dexstran-sulphate (DS-10000) and ribavirin 
against Punta Toro virus, effective concentration needed for reduction in viral replication for 
50 % of compound 15 is four and eleven times lower, respectively. However compound 15 is 
cytotoxic to uninfected Vero cell lines (MCC = 50; ≥20 μM). 
 
Table 4. Antiviral activity of selected 3-deazapurine derivatives of L-AA (2 and 3) against 
cytomegalovirus (CMV) and their cytotoxicity (MCC, CC50) on human embryonic lung cells 
(HEL). 
Comp. 
Cytotoxicity EC50 (μM)c 
MCCa CC50b 
CMV 
AD-169 cell line Davis cell line 
N
N
N
F
F
Cl O O
BnO OBn
(Z)-2  
exp. 1d >100 100 44.7 n. d. e 
exp. 2d >100 >100 44.7 44.7 
N N
N
Cl
F
       
exp. 1 100 >100 8.94 n. d. 
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exp. 2 >100 >100 8.94 8.94 
N
N
N
O O
BnO OBn
OCH3
H3CO
13
(Z) : (E) = 7 : 1
 
exp. 1 20 57.7 1.79 1.79 
exp. 2 ≥20 15.4 8.18 2.19 
Ganciclovir 
exp. 1 >350 394 6.25 n. d. 
exp. 2 >350 263 5.98 4.72 
Cidofovir 
exp. 1 >300 216 0.51 n. d. 
exp. 2 >300 153 0.70 0.51 
a Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology.  
b Cytotoxic concentration required to reduce cell growth by 50%. c Effective concentration required to reduce 
virus plaque formation by 50 %. Virus input was 100 plaque forming units (PFU).  d Experiment 1 or 2. e Not 
determined. 
 
Table 5. Antiviral activity of selected 3-deazapurine (2, 3) and 9-deazapurine derivatives of 
L-AA (15) against viruses: para-influenza-3, reovirus-1, Sindibis, Coxsackie B4 and Punta 
Toro virus and their cytotoxic effect (MCC) on african green monkey kidney epithelial cells 
(Vero cells). 
Comp. 
EC50a (μM) 
MCCb 
(μM) 
Para-
influenza-
3 virus 
Reovirus-
1 
Sindbis 
virus 
Coxsackie 
B4 virus 
Punta 
Toro 
virus 
N
N
N
F
F
Cl O O
BnO OBn
(Z)-2  
≥20 >20 >20 >20 14.5 12 
N N
N
Cl
F O O
BnO OBn
F
(Z) : (E) = 3 : 1
3
 
20 >20 >20 >20 >20 12 
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N
N
N
O O O
O
O OBn
BnO
BnO
BnO
(Z, Z'')-15
 
exp.1c 50 >10 >10 >10 >10 4.5 
exp.2c ≥20 >20 >20 >20 >20 8.9 
DS-5000 (μg/ml) >100 >100 >100 >100 >100 >100 
DS-10000 (μg/ml) 
exp. 1 >100 100 >100 10 10 20 
exp. 2 >100 >100 >100 8.9 58 20 
(S)-DHPA >250 >250 >250 >250 >250 >250 
Ribavirin 
exp. 1 >250 35 >250 >250 >250 250 
exp. 2 >250 112 >250 >250 >250 50 
a Effective concentration required to reduce virus-induced cypathogenicity by 50 %. b Minimum cytotoxic 
concentration required to cause a microscopically detectable alteration of normal cell morphology. c Experiment 
1 or 2. 
 
4. Experimental section 
 
4.1. Materials and general methods 
 
 Comercially available chemicals were purchased from Sigma Aldrich (Germany) and 
Acros (Belgium) and where used without purification. All solvents used in synthesis were 
analytical grade purity and dryed. Acetonitrile (CH3CN) was refluxed over calcium hydride 
(CaH2), distilled and stored over 3Å molecular sieves. 1,2-Dichloroethane (C2H4Cl2) and 
dichloromethane (CH2Cl2) were distilled from phosphorus pentoxide (P2O5) and stored over 
4Å molecular sieves. 1,4-Dioxane was dried with sodium and also stored over 4Å molecular 
sieves. Methanol (CH3OH) was stored over 3Å molecular sieves without distillation. 1,4-
Tetrahydrofuran (THF) was pre-dried over calcium hydride and refluxed over sodium 
benzophenone ketyl (sodium wire and benzophenone), distilled and stored over sodium. 
Melting points were determined on a Kofler micro hot-stage instrument (Reichter, Wien) and 
were uncorrected. Precoated Merck silica gel 60 F254 plates were used for thin-layer 
chromatography and spots were visualized by shortwave UV light (254 nm). Column 
chromatography was performed on Fluka silica gel (0.063−0.200 mm), with petroleum ether : 
ethylacetate, dichloromethane : methanol and dichloromethane as mobile phases. Additional 
purification by rechromatography afforded the analytical samples. 
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NMR spectroscopy 1H, 13C, 15N and 19F NMR spectra were recorded on a Varian Gemini 
300 spectrometer (Institute Ruđer Bošković, Zagreb) and Varian NMR System 600 and 
Varian Unity Inova 300 and Agilent Technologies DD2 300 MHz NMR spectrometers 
(National Institute of Chemistry, Ljubljana, Slovenia). Samples were measured in DMSO-d6 
solutions at 25 ºC in 5 mm NMR tubes. 1H and 13C NMR chemical shifts (δ) in ppm were 
referred to TMS (δ 0.0 ppm). 19F and 15N NMR chemical shifts were referenced externally 
with respect to trichlorofluoromethane (δF 0.0 ppm) and ammonia (δN 0.0 ppm). Individual 
resonances were assigned on the basis of their chemical shifts, signal intensities, multiplicity 
of resonances and H−H coupling constants. NOESY spectra were acquired with mixing times 
of 80 and 200 ms. 19F−13C NMR spectra utilized the one-bond coupling between fluorine and 
carbon (J = 240 Hz). 
The electron impact mass spectra and the purity of compounds were assessed by using 
Agilent Technologies 6410 Triple Quad LC/MS instrument equipped with electrospray 
interface and triple quadrupole analyzer (LC-MS/MS) in positive instrument mode. High 
performance LC was performed on Agilent 1100 series system with UV detection 
(photodiode array detector) using Zorbax C18 reverse-phase analytical column (2.1 x 30 mm; 
3.5 µm). All compounds used for biological evaluation showed > 95 % purity in HPLC-
MS/MS system. Exact mass of compounds were analysed by using HRMS with MALDI-
TOF/TOF analyser (4800 Plus MALDI-TOF/TOF, Applied Biosystems) in reflectron positive 
ion mode of the instrument. Elemental analyses indicated by the symbols of the elements were 
within ± 0.4 % of the theoretical values.  
 
4.2. Synthesis 
 
4.2.1. Procedure for preparation of 3,4-di-O-benzyl-5-(9-(3-bromo-1H-imidazo[4,5-
c]pyridine-9-yl)ethylidene)furan-2(5H)-one (1)  
3-Bromo-3-deazapurine base (A, 426.0 mg; 2.15 mmol) was disolved in N,O-
bis(trimethylsylil)acetamide (BSA, 0.6 ml; 2.15 mmol) and the reaction mixture was refluxed 
at room temperature for 1 hour and 30 minutes under inert atmosphere of argon. Excess BSA 
was evaporated under reduced pressure and yellow solid of silylated base was obtained. 6-
Hydroxy-2,3-di-O-benzyl-4,5-didehydro-L-ascorbic acid (HdBAA, 622.7 mg; 1.43 mmol) 
and silylated base were dissolved in dry acetonitrile (20.0 ml) and stirred under argon 
atmosphere at room temperature. TMSOTf (1.80 ml, 4 x 0.45 ml) was then added to the 
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reaction mixture and additionally stirred and heated at 55−70 °C over night. After evaporating 
the solvent under reduced pressure, crude yellowish-green product was obtained and washed 
with CH2Cl2 and saturated solution of NaHCO3. Organic layer was dried over MgSO4 and 
concentrated under reduced pressure. Crude product mixture was purified by silica gel column 
chromatography (dichloromethane : methanol = 25 : 1) and product 1 (Z : E = 4 : 1; 14.7 mg; 
1.32 %) was obtained as yellow oil by rechromatography (petroleum ether : etylacetate = 1 : 
1). MS (ESI): m/z = 518.2 ([M + H]+). Anal. Calcd. for C26H20BrN3O4 (517.06): C, 60.24; H, 
3.89; N, 8.11. Found: C, 60.19; H, 3.88; N, 8.13. 
(Z)-1: 13C NMR (DMSO-d6): δ 40.96 (C-6), 72.97 (OCH2-3), 73.94 (OCH2-2),  100.96 
(C-3’), 104.31 (C-5), 123.02 (C-2), 143.66 (C-2’), 127.8−128.9 (C6H5), 135.33/ 135.64/ 
135.72* (C-2a, C-3a), 135.33/ 135.64/ 135.72* (C-4’), 141.30 (C-6’), 141.98 (C-4), 142.10 (C-
5’), 143.66 (C-2’), 147.86 (C-8’), 163.57 (C-1) ppm. *Could not be unequivocally assigned. 
 
4.2.2. Method A. General method for preparation of 3-deazapurine derivatives of 4,5-
didehydro-5,6-dideoxy-L-ascorbic acid (2−4) 
Suspension of anhydrous 3-deazapurine base (B or C, 1 eq.) and (NH4)2SO4 (0.1 eq.) 
in HMDS (25-30 ml) was refluxed overnight under inert atmosphere of argon. Excess HMDS 
was evaporated under reduced pressure (0.1 mmHg) and silylated base was obtained as a 
solid. 5,6-di-O-acetyl-2,3-di-O-benzyl-L-ascorbic acid (dAdBAA, 0.7 eq.) and silylated base 
were dissolved in dry 1,2-dichloroethane (20−25 ml) and stirred at room temperature under 
argon atmosphere. TMSOTf (1.5 eq.) was added to the reaction mixture and the reaction 
mixture was heated at 55−70 °C with stirring over night. After evaporating the solvent under 
reduced pressure, crude product was obtained and washed with CH2Cl2 and saturated solution 
of NaHCO3. Organic layer was dried over MgSO4 and concentrated under reduced pressure. 
Crude product mixture was purified by silica gel column chromatography (petroleum ether : 
etylacetate) and by rechromatography (CH2Cl2 or petroleum ether : etylacetate). Compounds 
2−4 were obtained as oils. 
 
4.2.2.1. (3,4-di-O-benzyl-5-(9-(3-chloro-2,6-difluoro-1H-imidazo[4,5-c]pyridine-9-
yl)ethylidene)furan-2(5H)-one (2) and 3,4-di-O-benzyl-5-(7-(3-chloro-2,6-difluoro-1H-
imidazo[4,5-c]pyridine-7-yl)ethylidene)furan-2(5H)-one (3) 
Acording to method A, mixture of 3-chloro-2,6-difluoro-3-deazapurine (B, 618.2 mg, 
3.26 mmol) and dAdBAA (941.88 mg, 2.16 mmol) gave the crude product that was purified 
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by silica gel column chromatography (petroleum ether : etylacetate = 3 : 1). Products 2 (Z; 
174.0 mg; 31.60 %) and 3 (Z : E = 3 : 1; 157.0 mg; 28.51%) were obtained as white oils by 
rechromatography (CH2Cl2). (Z)-2: MS (ESI): m/z = 510.1 ([M + H]+). Anal. Calcd. for 
C26H18ClF2N3O4 (509.1): C, 61.24; H, 3.56; N, 8.24. Found: C, 61.27; H, 3.56; N, 8.26. 3: MS 
(ESI): m/z = 510.1 ([M + H]+). Anal. Calcd. for C26H18ClF2N3O4 (509.1): C, 61.24; H, 3.56; 
N, 8.24. Found: C, 61.26; H, 3.56; N, 8.25. 
(Z)-2: 13C NMR (DMSO-d6): 41.43 (C-6), 73.03 (OCH2-3), 73.96 (OCH2-2), 95.49 
(dd, 2JCF = 40.4 Hz, 4JCF = 8.0 Hz) (C-3’), 103.77 (C-5), 123.12 (C-2), 126.06 (dd, 2JCF = 33.5 
Hz, 4JCF = 3.3 Hz) (C-5’), 127.93−128.81 (C6H5), 135.31, 135.65 (C-2a, C-3a), 141.67 (dd, 3J 
CF = 11.5 Hz, 3JCF = 5.5 Hz) (C-4’), 142.19 (C-4), 148.02 (C-3), 148.28 (dd, 1J = 247.8 Hz, 3J 
= 15.9 Hz) (C-6’), 149.21 (C-8’), 150.46 (dd, 1JCF = 229.6 Hz, 3J CF = 15.4 Hz) (C-2’), 163.49 
(C-1) ppm. 
(Z)-3: 41.56 (C-6), 73.3 (OCH2-3), 73.99 (OCH2-2), 101.21 (dd, 2JCF = 34.8 Hz, 4JCF = 
8.8 Hz) (C-3’), 102.84 (C-5), 116.37 (dd, 2JCF = 26.9 Hz, 4JCF = 3.8 Hz) (C-5’), 123.28 (C-2), 
127.81−128.81 (C6H5), 135.32, 135.67 (C-2a, C-3a), 142.80 (C-4), 143.62 (dd, 1J = 242.0 Hz, 
3J = 17.0 Hz) (C-6’), 147.97 (C-3), 149.70 (dd, 1JCF = 229.6 Hz, 3J CF = 14.3 Hz) (C-2’), 
151.02 (C-8’), 153.15 (dd, 3JCF = 7.1 Hz, 3JCF = 4.4 Hz) (C-4’), 163.55 (C-1) ppm. 
 
4.2.2.2. 3,4-bis(benzyloxy)-5-(2-(4-chloro-1H-imidazo[4,5-c]pyridine-1-yl)ethylidene)furan-
2(5H)-one (4) 
Suspension of anhydrous 6-chloro-3-deazapurine (500.0 mg, 3.26 mmol) and 
dAdBAA (941.0 mg, 2.16 mmol) gave after reaction, according to method A, the crude 
product that was purified by silica gel column chromatography (petroleum ether : etylacetate 
= 2 : 1). Compound 5 (Z : E = 1 : 1; 255.8 mg; 25.08 %) was obtained as white oil by 
rechromatoraphy (petroleum ether : etylacetate = 1 : 1). MS (ESI): m/z = 474.2 ([M + H]+). 
Anal. Calcd. for C26H20ClN3O4 (473.11): C, 65.89; H, 4.25; N, 8.87. Found: C, 65.93; H, 
4.25; N, 8.90. 
(Z)-4: 13C NMR (DMSO-d6): 41.45 (C-6), 73.07 (OCH2-3), 74.01 (OCH2-2), 104.37 
(C-5), 114.83/ 114.88* (C-3’), 123.13/ 124.67* (C-2), 126.29/ 126.45* (C-5’), 127.9−129.0 
(C6H5), 132.72/ 132.77* (C-6’), 135.4−135.7 (C-2a, C-3a), 140.75/ 140.77* (C-2’), 142.15 
(C-4), 148.15 (C-3), 149.13 (C-8’), 150.99 (C-4’), 163.65/163.79* (C-1) ppm. *Chemical 
shifts between E and Z isomers could not be distinguished. 
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(E)-4: 13C NMR (DMSO-d6): 41.45 (C-6), 73.63 (OCH2-3), 74.01 (OCH2-2), 109.70 
(C-5), 114.83/ 114.88* (C-3’), 123.13/ 124.67* (C-2), 126.29/126.45* (C-5’), 127.9−129.0 
(C6H5), 132.77 (C-6’), 135.4−135.7 (C-2a, C-3a), 140.75/ 140.77* (C-2’), 141.83 (C-4), 
148.53 (C-8’), 148.94 (C-3), 150.99 (C-4’), 163.65/ 163.79* (C-1) ppm. *Chemical shifts 
between E and Z isomers could not be distinguished. 
   
4.2.3. Method B. General procedure for preparation of 3-deazapurine derivatives of imino-L-
ascorbic acid (5−7) 
Ammonia was induced in a stirred solution of compounds 1, 2 or 4 (0.11−0.25 mmol), 
in anhydrous methanol (5−10 ml) and 1,4-dioxane (5−10 ml) in ice-cold bath (0 °C). After 
saturation of ammonia, mixture was additionally stirred overnight at room temperature. 
Methanol, 1,4-dioxane and surplus ammonia were removed at reduced pressure. Purification 
of crude residue by silica gel column chromatography using dichloromethane : methanol = 10 
: 1 gave desired compounds 5−7, respectively as solids. 
 
4.2.3.1. 3,4-di-O-benzyl-5-hydroxy-5-(7-(6-chloro-3H-imidazo[4,5-c]pyridine-7-yl)ethyl)-1H-
pyrrolo-2(5H)-one (5) 
According to procedure B, ammonolysis of compound 3 (96.2 mg; 0.20 mmol) gave 
crude residue which was purified by silica gel column chromatography (dichloromethane : 
methanol = 30 : 1) and gave compound 5 as beige solid (16.5 mg;  16.81 %, m.p.= 
216−218°C). MS (ESI): m/z = 491.3 ([M + H]+). Anal. Calcd. for C26H23ClN4O4 (490.14): C, 
63.61; H, 4.72; N, 11.41. Found: C, 63.69; H, 4.72; N, 11.42. 
13C NMR (DMSO-d6): 38.60 (C-5), 41.64 (C-6), 72.10 (OCH2-3), 73.27 (OCH2-2), 
81.74 (C-4), 114.79 (C-3’), 123.12 (C-2), 127.60 (C-5’), 127.6−128.7 (C6H5), 136.23 (C-2a), 
132.66 (C-6’), 136.70 (C-3a), 140.54 (C-2’), 149.03 (C-8’), 151.01 (C-4’), 153.23 (C-3), 
167.96 (C-1) ppm. 
 
4.2.3.2. 3,4-di-O-benzyl-5-(9-(3-bromo-1H-imidazo[4,5-c]pyridine-9-yl)ethyl)-5-hydroxy-1H-
pyrrolo-2(5H)-one (6) 
Ammonolysis of compound 1 (58.0 mg; 0.11 mmol) in accordance with procedure B, 
gave crude residue which was purified by silica gel column chromatography 
(dichloromethane : methanol = 10 : 1) and resulted in isolation of compound 6 in the form of 
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transparent oil (9.7 mg; 16.47 %). HRMS calcd. for C26H23BrN4O4: m/z = 535.0967 ([M + 
H]+). Found MS (TOF): m/z = 535.0962 ([M + H]+). 
13C NMR (DMSO-d6): 38.41 (C-5), 41.09 (C-6), 72.05 (OCH2-3), 73.26 (OCH2-2), 
81.72 (C-4), 100.85 (C-3’), 123.11 (C-2), 127.6−128.7 (C6H5), 135.61 (C-4’), 136.25, 136.70 
(C-2a, C-3a), 141.30 (C-6’), 142.22 (C-5’), 143.52 (C-2’), 147.85 (C-8’), 153.16 (C-3), 
167.92 (C-1) ppm. 
 
4.2.3.3. 5-(9-(6-amino-3-chloro-2-fluoro-1H-imidazo[4,5-c]pyridine-9-yl)ethyl)-3,4-di-O-
benzyl-5-hydroxy-1H-pyrrolo-2(5H)-one (7) 
In accordance to procedure B, amonolysis of compound 2 (130.0 mg; 0.25 mmol) gave 
crude residue which was purified by silica gel column chromatography (dichloromethane : 
methanol = 10 : 1) which resulted in isolation of the compound 7 as white solid (24.3 mg; 
18.55 %; m.p. = 199−202 °C). MS (ESI): m/z = 524.2 ([M + H]+). Anal. Calcd. for 
C26H23ClFN5O4 (523.14): C, 59.60; H, 4.42; N, 13.37. Found: C, 59.71; H, 4.41; N, 13.35.  
13C NMR (DMSO-d6): 38.55 (C-5), 41.05 (C-6), 72.03 (OCH2-3), 73.21 (OCH2-2), 
81.64 (C-4), 82.67 (d, 2JCF = 44.0 Hz) (C-3’), 123.06 (C-2), 126.02 (d, 4J CF = 2.2) (C-5’), 
127.59−128.63 (C6H5), 136.10 (d, 3JCF = 7.1 Hz) (C-4’), 136.20, 136.69 (C-2a, C-3a), 143.86 
(C-8’), 148.48 (d, 3JCF = 20.9 Hz) (C-6’), 153.67 (d, 1J CF = 219.2 Hz) (C-2’), 153.13 (C-3), 
167.88 (C-1) ppm. 
 
4.2.4. Procedure for preparation of 5-(2-(7-chloro-4,6-difluoro-3H-imidazo[4,5-c]pyridine-3-
yl)ethylidene)-3,4-dihydroxyfuran-2(5H)-one (8) 
To solution of compound 2 (117.3 mg; 0.23 mmol) in anhydrous dichloromethane (3 
ml), BCl3 (0.76 ml; 0.76 mmol) was added dropwise in 10 portions at temperature -70 °C 
under argon atmosphere and mixture was stirred for 30 minutes. Temperature raised gradually 
to room temperature and reaction solution stirred over night. Reaction was terminated by 
adding solution of dichloromethane : methanol in ratio 1 : 1 (10 ml) and concentrated by 
evaporation in vacuo. Purification of crude product mixture by silica gel column 
chromatography (CH2Cl2 : MeOH = 5 : 1) gave  of compound 8 as white oil (Z : E = 10 : 1; 
15.3 mg; 20.18 %). MS (ESI): m/z = 330.0 ([M + H]+). Anal. Calcd. for C12H6ClF2N3O4 
(329.0): C, 43.72; H, 1.83; N, 12.75. Found: C, 43.77; H, 1.83; N, 12.75. 
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13C NMR (DMSO-d6): ≈ 42 (C-6), ≈ 99 (C-5), ≈ 116 (C-5’), ≈ 143 (C-4), ≈ 143 (C-3), 
≈ 150 (C-8’) ppm. Chemical shifts of C-1, C-2, C-3’, C-2’, C-6’ carbons were not detectable 
because of the small quantity of the compound and it also decomposes over time. 
 
4.2.5. Procedure for preparation of 7-bromo-7-deazapurine derivative of 4,5-didehydro-5,6-
dideoxy-L-ascorbic acid (3,4-di-O-benzyl-5-(1-(7-bromo-3H-pyrrolo[2,3-d]pyrimidine-1-
yl)ethylidene)furan-2(5H)-one, 9) 
Suspension of anhydrous 7-bromo-7-deazapurine base (D, 500.0 mg; 2.52 mmol) and 
(NH4)2SO4 (33.3 mg; 0.25 mmol) in HMDS (25 ml) was refluxed overnight under inert 
atmosphere of argon. Excess HMDS was evaporated in vacuo. Suspension of silylated base D 
and dAdBAA (727.2 mg; 1.67 mmol) in dry 1,2-dichloroethane (25 ml) was stirred under 
inert atmosphere of argon at room temperature. TMSOTf (1.5 eq.) was then added to the 
mixture and was heated at 55−70 °C and stirred over night. Crude product was obtained after 
evaporating the solvent in vacuo, and extracted with CH2Cl2 and saturated solution of 
NaHCO3. Organic layer was dried over MgSO4 and concentrated in vacuo. Compound 9 (8.4 
mg; 0.97 %; m.p. = 123−125 °C) was obtained as greenish-yellow solid by purification of 
solid product by silica gel column chromatography (dichloromethane : methanol = 70 : 1) and 
rechromatography (dichloromethane : methanol = 50 : 1). HRMS Calcd. for C26H20BrN3O4: 
m/z = 518.0710 ([M + H]+). Found MS (TOF): m/z = 518.0704 ([M + H]+). 
13C NMR (DMSO-d6): δ 50.07 (C-6), 73.04 (OCH2-3), 74.05 (OCH2-2), 86.82 (C-7’), 
102.51 (C-5), 119.20 (C-5’), 123.48 (C-2), 123.72 (C-8’), 127.9−128.8 (C6H5), 135.31, 
135.68 (C-2a, C-3a), 136.06 (C-6’), 141.90 (C-2’), 143.40 (C-4), 147.93 (C-3), 155.93 (C-4’), 
163.58 (C-1) ppm.  
 
4.2.6. Procedure for preparation of 6-chloro-7-iodo-7-deazapurine derivative of 4,5-
didehydro-5,6-dideoxy-L-ascorbic acid (3,4-di-O-benzyl-5-(9-(6-chloro-7-iodo-7H-
pyrrolo[2,3-d]pyrimidine-9-yl)ethylidene)furan-2(5H)-one, 10) 
Solution of triphenyl-phosphine (PPh3, 241.3 mg; 0.92 mmol), diethyl 
azodicarboxylate (DEAD, 0.18 ml; 0.92 mmol) in absolute dry tetrahydrofuran (THF, 3.8 ml) 
was stirred under inert argon atmosphere for one hour at -40 − -50 °C. Solution of 6-chloro-7-
iodo-7-deazapurine (E, 140.0 mg; 0.50 mmol) and THF (1.5 ml) was then added to reaction 
mixture and stirred for another 1 hour at -40 − -50 °C temperature, under inert atmosphere of 
argon. 6-Hydroxy-2,3-di-O-benzyl-4,5-didehydro-L-ascorbic acid (HdBAA, 185.4; 0.55 
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mmol) was dissolved in absolute dry THF (1.8 ml) and added to the mixture which was then 
stirred at -40 − -50 °C which was risen gradually to room temperature and stirred over night. 
Crude reaction product was obtained by evaporation of raw reaction mixure in vaccuo and 
was purified by to silica gel column chromatography (dichloromethane : methanol = 175 : 1) 
and rechromatoraphy (dichloromethane : methanol = 120 : 1) which resulted in gaining white 
powder of compound 10 (Z : E = 9 : 1; 93.0 mg; 30.95 %; m.p.= 114−117 °C). MS (ESI): m/z 
= 599.1 ([M]+). Anal. Calcd. for C26H19ClIN3O4 (599.01): C, 52.06; H, 3.19; N, 7.01. Found: 
C, 52.11; H, 3.19; N, 7.00. 
13C NMR (DMSO-d6): δ 50.92 (C-6), 57.38 (C-7’), 72.80 (OCH2-3), 73.74 (OCH2-2), 
101.09 (C-5), 114.30 (C-5’), 123.30 (C-2), 128.94−129.99 (C6H5), 133.13 (C-8’), 136.12, 
136.53 (C-2a, C-3a), 142.55 (C-4), 147.36 (C-3), 148.11 (C-6’), 150.05 (C-4’), 150.31 (C-2’), 
167.30 (C-1) ppm.  
 
4.2.7. Method C. General procedure for preparation of 7-deazapurine derivatives of imino-L-
ascorbic acid (11, 12) 
Ammonia was induced in stirred solution of compounds 9 or 10 (0.13−0.14 mmol) and 
anhydrous methanol (2.0−2.25 ml) and dioxane (2.0−2.25 ml) in ice-cold bath (0°C). After 
saturation with ammonia, mixture was stirred overnight at room temperature. Methanol, 1,4-
dioxane and surplus ammonia were removed in vacuum. Purification of crude residue by 
silica gel column chromatography using dichloromethane : methanol = 10 : 1 gave 
compounds 11 and 12 as transparent oil and as white powder, respectively. 
 
4.2.7.1. 3,4-di-O-benzyl-5-(2-(5-bromo-3H-pyrrolo[2,3-d]pyrimidine-ethyl)-5-hydroxy-1H-
pyrrolo-2(5H)-one (11) 
According to procedure C, ammonolysis of compound 9 (65.0 mg; 0.14 mmol) gave 
solid residue which was purified by silica gel column chromatography (dichloromethane : 
methanol = 10 : 1) which gave compound 11 as transparent oil (1.0 mg; 3.24 %). MS (ESI): 
m/z = 535.2 ([M + H]+). Anal. Calcd. for C26H23BrN4O4 (534.09): C, 58.33; H, 4.33; N, 7.01. 
Found: C, 58.37; H, 4.32; N, 6.99. 
13C NMR (DMSO-d6): δ 37.7 (C-5), 51.3 (C-6), 72.12 (OCH2-3), 73.37 (OCH2-2), 
81.82 (C-4), 86.5 (C-7’), 121.5 (C-5’), 123.0 (C-8’), 123.25 (C-2), 127.6−128.4 (C6H5), 
136.13 (C-2a), 136.4 (C-6’), 136.71 (C-3a), 142.0 (C-2’), 153.21 (C-3), 155.5 (C-4’), 167.85 
(C-1) ppm.  
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4.2.7.2. 3,4-di-O-benzyl-5-(9-(6-chloro-7-iodo-7H-pyrrolo[2,3-d]pyrimidine-9-yl)-vinyl)-5-
hydroxy-1H-pyrrolo-2(5H)-one (12) 
According to procedure C, ammonolysis of compound 10 (80.0 mg; 0.13 mmol) gave 
crude residue which was purified by silica gel column chromatography (dichloromethane : 
methanol = 40 : 1) and resulted in isolation of compound 12 as white powder (13.2 mg; 16.05 
%; m.p.= 165−168 °C). MS (ESI): m/z = 615.2 ([M + H]+). Anal. Calcd. for C26H20ClIN4O4 
(614.02): C, 50.79; H, 3.28; N, 9.11. Found: C, 50.90; H, 3.28; N, 9.09. 
13C NMR (DMSO-d6): δ 56.17 (C-7’), 72.02 (OCH2-3), 73.27 (OCH2-2), 81.23 (C-4), 
116.90 (C-5’), 117.26 (C-5), 122.59 (C-6), 123.54 (C-2), 127.4−128.4 (C6H5), 132.92 (C-8’), 
136.38, 136.72 (C-2a, C-3a), 149.66 (C-4’), 151.32 (C-2’), 151.43 (C-6’), 153.50 (C-3), 
167.74 (C-1) ppm.  
 
4.2.8. Method D. General procedure for 9-deazapurine derivatives of 4,5-didehydro-5,6-
dideoxy-L-ascorbic acid (13−15) 
Solution of triphenyl-phosphine (PPh3, 0.66 eq.), diethyl azodicarboxylate (DEAD, 
0.66 eq.) in absolute dry tetrahydrofuran (THF, 4.0 ml) was stirred under inert argon 
atmosphere for one hour at -40 − -50 °C. Solution of 7-deazapurine bases (F or G, 1 eq.) and 
THF (4.5 ml) was then added to reaction mixture and stirred an hour at -40 − -50 °C, under 
inert atmosphere of argon. 6-Hydroxy-2,3-di-O-benzyl-4,5-didehydro-L-ascorbic acid 
(HdBAA, 0.9−1.0 eq.) was soluted in absolute dry THF (5.0 ml) and was added to the 
mixture and stirred at -40 − -50 °C which was gradually risen to room temperature and stirred 
over night. Crude reaction product was retained by evaporation of the raw reaction mixure in 
vacuo and was purified by silica gel column chromatography (n-hexane : ethyl-acetate = 2 : 1, 
dichloromethane : methanol = 175 : 1) and rechromatography (n-hexane : ethyl-acetate = 1 : 
1, dichloromethane : methanol = 120 : 1) which gave compounds 13−15.  
 
4.2.8.1. 3,4-di-O-benzyl-5-(7-(2,4-dimethoxy-5H-pyrrolo[3,2-d]pyrimidine-7-
yl)ethylidene)furan-2(5H)-one (13) 
According to procedure D, solution of 2,6-dimethoxy-9-deazapurine (F, 250.0 mg; 1.4 
mmol), PPh3 (587.5 mg; 2.24 mmol), DEAD (0.44 ml; 2.24 mmol) and HdBAA (410.0 mg; 
1.2 mmol) in THF (13.5 ml) was stirred under inert argon atmosphere at -40 − -50 °C for 3 
hours and then at room temperature over night. Crude reaction product was purified by silica 
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gel column chromatography (n-hexane : ethyl-acetate = 2 : 1) and rechromatoraphy (n-hexane 
: ethyl-acetate = 1 : 1) which resulted in isolation of transparent oil of compound 13 (106.0 
mg; 18.18 %). MS (ESI): m/z = 500.3 ([M + H]+). Anal. Calcd. for C28H25N3O6 (499.17): C, 
67.33; H, 5.04; N, 8.41. Found: C, 67.18; H, 5.05; N, 8.42. 
13C NMR (DMSO-d6): δ 43.25 (C-6), 53.45 (OCH3-6’), 53.95 (OCH3-2’), 72.95 
(OCH2-3), 73.90 (OCH2-2), 100.83 (C-9’), 104.73 (C-5), 111.27 (C-5’), 123.09 (C-2), 
127.5−129.3 (C6H5), 134.09 (C-8’), 135.36, 135.69 (C-2a, C-3a), 141.94 (C-4), 148.09 (C-3), 
151.62 (C-4’), 157.03 (C-6’), 159.45 (C-2’), 163.79 (C-1) ppm.   
 
4.2.8.2. 3,4-di-O-benzyl-5-(1-(3H-pyrrolo[3,2-d]pyrimidine-4(5H)-one-1-yl)ethylidene)furan-
2(5H)-one (14) and 1,7-di-(5-(3,4-di-O-benzyl-furan-2(5H)-one)etiliden)-3H-pirolo[3,2-
d]pyrimidine-4(5H)-on (15) 
According to procedure D, solution of 9-deazahypoxanthine (G, 200.0 mg; 1.48 
mmol), PPh3 (587.5 mg; 2.24 mmol), DIAD (0.44 ml; 2.24 mmol) and HdBAA (500.0 mg; 
1.48 mmol) in THF (13.5 ml) was stirred under inert argon atmosphere at -40 − -50 °C for 3 
hours and over night at room temperature. Purification of crude product by silica gel column 
chromatography (n-hexane : ethyl-acetate = 1 : 1) and rechromatography with the same 
eluent, gave white powders of compounds 14 (47.6 mg; 28.81 %; m.p. = 114−117 °C) and 15 
(97.1 mg; 8.29 %; m.p. = 54−57 °C). (Z)-14: MS (ESI): m/z = 457.3 ([M]+). Anal. Calcd. for 
C26H23N3O5 (457.16): C, 68.26; H, 5.07; N, 9.19. Found: C, 68.31; H, 5.06; N, 9.21. (Z, Z’’)-
15: MS (ESI): m/z = 776.4 ([M + H]+). Anal. Calcd. for C46H37N3O9 (775.25): C, 71.22; H, 
4.81; N, 5.42. Found: C, 71.20; H, 4.81; N, 5.43. 
(Z)-14: 13C NMR (DMSO-d6): δ 40.5 (C-6), 72.93 (OCH2-3), 74.00 (OCH2-2), 102.96 
(C-9’), 104.39 (C-5), 116.99 (C-5’), 122.91 (C-2), 127.8 (C-8’), 127.9−128.8  (C6H5), 135.38, 
135.73 (C-2a, C-3a), 142.23 (C-4), 144.07 (C-4’), 144.19 (C-2’), 148.12 (C-3), 152.98 (C-6’), 
163.75 (C-1) ppm. 
(Z, Z’’)-15: 13C NMR (DMSO-d6): δ 40.3 (C-6), 42.71 (C-6’’), 72.94 (OCH2-3), 72.94 
(OCH2-3’’), 73.97/ 73.99* (OCH2-2, OCH2-2’’), 102.80 (C-9’), 104.38 (C-5), 104.85 (C-5’’), 
115.99 (C-5’), 122.94/ 123.14* (C-2, C-2’’), 127.9−128.8 (C6H5, C6H5’’), 131.60 (C-8’), 
135.35, 135.73 (C-2a, C-2a’’, C-3a, C-3a’’), 141.91 (C-4’’), 142.20 (C-4), 144.49 (C-4’), 
144.78 (C-2’), 148.04/ 148.07* (C-3, C-3’’), 153.26 (C-6’), 163.70 (C-1), 163.70 (C-1’’) 
ppm. *Could not be unequivocally assigned. 
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4.2.9. Method E. General procedure for preparation of 9-deazapurine derivatives of imino-L-
ascorbic acid (16−19)  
Ammonia was induced in stirred solution of compounds 13−15 (0.06−0.21 mmol) and 
anhydrous methanol (1.5−3.0 ml) and dioxane (1.0−3.0 ml) in ice-cold bath (0°C). After 
saturation of ammonia, mixture was stirred overnight at room temperature. Methanol, 1,4-
dioxane and surplus ammonia were removed in vacuum. Purification of crude residue by 
silica gel column chromatography using dichloromethane : methanol (25 : 1 or 15 : 1 ratio), 
obtained compounds 16-19 as solids, respectively. 
 
4.2.9.1. 3,4-di-O-benzyl-5-hydroxy-5-(7-(2,4-dimethoxy-5H-pyrrolo[3,2-d]pyrimidine-7-
yl)ethyl)-1H-pyrrolo-2(5H)-one (16) 
 Solution of compound 13 (92.5 mg; 0.19 mmol) in accordance with method D gave 
crude residue which was purified by silica gel column chromatography using dichloromethane 
: methanol = 25 : 1 and resulted in isolation of white powder of compound 16 (31.65 mg; 
33.01 %; m.p.= 85−88 °C). HRMS Calcd. for C28H28N4O6: m/z = 517.2081 ([M + H]+). Found 
MS (TOF): m/z = 517.2084 ([M + H]+). 
13C NMR (DMSO-d6): δ 38.25 (C-5), 44.04 (C-6), 53.46 (OCH3-6’), 53.89 (OCH3-2’), 
71.92 (OCH2-3), 73.14 (OCH2-2), 81.72 (C-4), 100.20 (C-9’), 111.22 (C-5’), 123.06 (C-2), 
127.4−128.5 (C6H5), 133.90 (C-8’), 136.32, 136.75 (C-2a, C-3a), 151.39 (C-4’), 153.11 (C-3), 
156.88 (C-6’), 159.29 (C-2’), 167.93 (C-1) ppm.   
 
4.2.9.2. 3,4-di-O-benzyl-5-hydroxy-5-(1-(3H-pyrrolo[3,2-d]pyrimidine-4(5H)-one-1-yl)ethyl)-
1H-pyrrolo-2(5H)-one (17) 
 In accordance with method D, ammonolysis of compound 14 (94.0 mg; 0.21 mmol) 
resulted in gaining crude residue which was purified by silica gel column chromatography 
using dichloromethane : methanol = 15 : 1 and white powder of compound 17 was obtained 
(28.5 mg;  28.73 %; m.p.= 205−208 °C). HRMS Calcd. for C26H24N4O5: m/z = 495.1639 ([M 
+ Na]+). Found MS (TOF): m/z = 495.1638 ([M+Na]+). 
13C NMR (DMSO-d6): δ 36.24 (C-5), 41.05 (C-6), 72.04 (OCH2-3), 73.27 (OCH2-2), 
81.90 (C-4), 102.80 (C-9’), 117.18 (C-5’), 123.08 (C-2), 127.5 (C-8’), 127.7−128.6 (C6H5), 
136.30, 136.77 (C-2a, C-3a), 143.94 (C-4’), 144.34 (C-2’), 153.16 (C-6’), 153.38 (C-3), 
167.96 (C-1) ppm. 
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4.2.9.3. 1-(5-(3,4-di-O-benzyl-5-hydroxy-furan-2(5H)-one)ethyl)-7-(5-(3,4-di-O-benzyl-5-
hydroxy-furan-2(5H)-one)ethyl)-3H-pyrrolo[3,2-d]pyrimidine-4(5H)-one (18 and 19) 
In accordance with method D, ammonolysis of compound 15 (43.2 mg; 0.06 mmol) 
resulted in gaining crude residue which was purified by silica gel column chromatography 
using dichloromethane : methanol = 15 : 1 and white powders of compounds 18 (11.45 mg; 
50.44 %; m.p. = 103−106 °C) and 19 (11.78 mg; 51.89 %; m.p. = 101−103 °C) were isolated. 
18: HRMS Calcd. for C46H43N5O9: m/z = 832.2952 ([M + Na]+). Found MS (TOF): m/z = 
832.2951 ([M + Na]+). 19: HRMS Calcd. for C46H43N5O9: m/z = 832.2952 ([M + Na]+). 
Found MS (TOF): m/z = 832.2946 ([M + Na]+). 
18: 13C NMR (DMSO-d6): δ 36.19 (C-5), 38.6 (C-5’’), 41.21 (C-6), 43.88 (C-6’’), 
71.96/ 72.04* (OCH2-3, OCH2-3’’), 73.29 (OCH2-2), 73.29 (OCH2-2’’), 81.75 (C-4’’), 81.91 
(C-4), 101.97 (C-9’), 116.15 (C-5’), 123.08/ 123.12* (C-2, C-2’’), 127.6−128.5 (C6H5, 
C6H5’’), 131.44 (C-8’), 136.30, 136.77 (C-2a , C-2a’’, C-3a, C-3a’’), 144.39 (C-4’), 144.70 
(C-2’), 153.17 (C-6’), 153.34/ 153.40* (C-3, C-3’’), 167.95 (C-1), 167.95 (C-1’’) ppm. 
*Could not be unequivocally assigned. 
19: 13C NMR (DMSO-d6): δ 36.16 (C-5), 38.6 (C-5’’), 41.17 (C-6), 43.86 (C-6’’), 
71.95/72.03* (OCH2-3, OCH2-3’’), 73.26 (OCH2-2), 73.26 (OCH2-2’’), 81.75 (C-4’’), 81.90 
(C-4), 101.95 (C-9’), 116.14 (C-5’), 123.06/ 123.09* (C-2, C-2’’), 127.6−128.5 (C6H5, 
C6H5’’), 131.41 (C-8’), 136.29, 136.76 (C-2a , C-2a’’, C-3a, C-3a’’), 144.37 (C-4’), 144.68 
(C-2’), 153.15 (C-6’), 153.33/ 153.38* (C-3, C-3’’), 167.93 (C-1), 167.93 (C-1’’) ppm. 
*Could not be unequivocally assigned. 
 
4.3. Biological tests 
 
4.3.1. Cytostatic and antiviral activity assays 
 
4.3.2. Cell culturing 
Cell lines HeLa (cervical carcinoma), SW620 (colorectal adenocarcinoma, metastatic), 
MiaPaCa-2 (pancreatic carcinoma), HepG2 (hepatocellular carcinoma), CFPAC-1 (pancreatic 
adenocarcinoma cells) and 3T3 (mouse embryonic fibroblast cell line), were cultured as 
monolayers and maintained in Dulbecco's modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 2mM L-glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin in a humidified atmosphere with 5% CO2 at 37˚C.  
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4.3.3. Proliferation assays 
The panel cell lines were inoculated onto a series of standard 96-well microtiter plates 
on day 0, at 5000 cells per well. Test agents were then added in five, 10-fold dilutions (0.01 to 
100 µM) and incubated for further 72 hours. Working dilutions were freshly prepared on the 
day of testing in the growth medium. The solvent (DMSO) was also tested for eventual 
inhibitory activity by adjusting its concentration to be the same as in the working 
concentrations (DMSO concentration never exceeded 0.1%). After 72 hours of incubation, the 
cell growth rate was evaluated by performing the MTT assay: experimentally determined 
absorbance values were transformed into a cell percentage growth (PG) using the formulas 
proposed by NIH and described previously [24]. This method directly relies on control cells 
number at the day of assay because it compares the growth of treated cells with the growth of 
untreated cells in control wells on the same plate − the results are therefore a percentile 
difference from the calculated expected value.  
The IC50 values for each compound were calculated from dose-response curves using 
linear regression analysis by fitting the mean test concentrations that give PG values above 
and below the reference value. If, however, all of the tested concentrations produce PGs 
exceeding the respective reference level of effect (e.g. PG value of 50) for a given cell line, 
the highest tested concentration is assigned as the default value (in the screening data report 
that default value is preceded by a ">" sign). Each test point was performed in quadruplicate 
in three individual experiments. The results were statistically analyzed (ANOVA, Tukey post-
hoc test at p < 0.05). Finally, the effects of the tested substances were evaluated by plotting 
the mean percentage growth for each cell type in comparison to control on dose response 
graphs. 
 
5. Conclusion 
 
In this paper we describe synthesis of new types of 3-, 7- and 9-deazapurine derivatives of 
L-ascorbic (1−4, 8−10 and 13−15) or imino-L-ascorbic acid (5−7, 11, 12 and 16−19) and their 
in vitro effects on the growth of tumour cell lines, normal fibroblasts and antiviral activity. 
Amongst 3-deazapurine derivatives of L-AA (1−4, 8) and imino-L-AA (5−7), 2,6-difluoro-3-
deazapurine derivative of L-ascorbic acid (3) has shown strong antiviral effect against 
cytomegalovirus (AD-169 and Davis cell strain) at the same level of inhibitory concentration 
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as drug ganciclovir. Also, compound 3 has not shown any cytostatic effects against tested 
normal uninfected human cells: embryonal lung (HEL), cervical carcinoma (HeLa), normal 
murine fibroblasts (3T3) nor against evaluated uninfected animal cells: Madin Darby canine 
kidney (MDCK), Crandell-Rees feline kidney cells (CRFK). However, removal of benzyl 
protection groups at C-2 and C-3 positions of L-AA moiety as in compound 8 and conversion 
of L-AA into imino-L-AA in analogue 7, resulted in loss of anti-CMV activity. Compound 3 
and its N-9 regioisomer (2) have exhibited highly comparable antiviral effects against Punta 
Toro virus, but concomitantly showed cytostatic effects on human uninfected Vero cells. 
Besides that, compound 2 has exerted moderate antiviral activity against Coxsackie B4 virus 
in Vero cells and no cytostatic effects on cervical carcinoma cells (HeLa) infected with the 
same virus. 7-Deazapurine derivatives of L-AA (9, 10) and imino-L-AA (12) showed no 
marked cytostatic nor antiviral activity. In contrary, 9-deazapurine derivatives of L-ascorbic 
acid (13, 15) and imino-L-ascorbic acid (18) have exhibited strong cytostatic effects against 
murine leukemia cell lines (L1210/0) in micromolar concentrations (IC50), while 2,6-
dimethoxy L-ascorbic acid derivative (13) also against CEM/0 cells. In addition, 9-
deazahypoxanthine derivative disubstituted with two L-ascorbic acid moieties (15) has also 
shown strong antitumoural activity against HeLa cells. Conversion of L-ascorbic acid moiety 
of compound 15 into imino-L-ascorbic acid, resulted in gaining compound 18 which 
expressed a cytostatic effect against pancreatic carcinoma cells (MiaPaCa-2). 9-Deazapurine 
derivatives 13, 15 and 18 have not shown any cytotoxic effects on normal murine fibroblasts 
(3T3). Besides that, 9-deazahypoxanthine derivative disubstituted with two L-AA moieties at 
N-1 and N-7 positions (15) exhibited even stronger antiviral activity against Punta Toro virus 
in accordance to EC50 values of compounds 2 and 3 against the same virus with four and 
eleven times lower values of effective concentration in comparison to inhibitory activity of 
dexstran-sulphate (DS-10000) and ribavirin, respectively. However compound 15 is also 
cytotoxic to uninfected Vero cell lines. 
Compounds with the most prominent antitumoural activities, 9-deazapurine derivative of 
L-AA (13) and 9-deazapurine derivatives of imino-L-AA (15 and 18) will serve as leading 
molecules for synthetic structure modification with the aim to develop more selective and 
more active antitumoural substrates in this class of compounds. In addition to that, compound 
3 will also be a model skeleton for developing even more effective anti-CMV substrate. 
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Supplementary 1. 19F NMR chemical shifts (δ/ ppm) and F−F coupling constants (J/ Hz) of 
compounds 2, 3, 7 and 8. 
Comp. 2 3 7 8 
F-2 -81.52 (d, 4J = 12.4) -81.51 (d, 4J = 13.3) -85.20 (s) -82.29 (d, 4J = 13.0) 
F-6 -85.02 (d, 4J = 12.4) -86.99 (d, 4J = 13.2) - -87.79 (d, 4J = 13.0) 
a 19F NMR chemical shifts are reported with respect to chemical shift of trichlorofluoromethane (δ 0.0 ppm). 
 
Supplementary 2. 15N NMR chemical shifts (δ/ ppm)a of compounds 1−7 and 12−18. 
Comp. N-1’ N-3’ N-7’ N-9’ 
NH/ NH'' 
imino-L-AA 
NH2-6' 
1 302 - 245 157 - - 
2 * - 240 163 - - 
(Z)-3 * - 158 243 - - 
(E)-3 * - 157 243 - - 
(Z)-4 291 - 154 243 - - 
(E)-4 291 - 155 244 - - 
5 291 - 156 243 125/ - - 
6 302 - 245 160 125/ - - 
7 180 - 235 154 127/ - 78 
(Z)-12 * * - 163 128/ - - 
(Z)-13 * * 138 - 125/ - - 
(Z)-14 171 237 142 - - - 
(Z, Z'')-15 172 237 147 - - - 
16 * * 138 - 125/ - - 
17 172 236 142 - 125/ - - 
18 173 236 150 - 125/ 125 - 
a 15N NMR chemical shifts are referenced externally to chemical shift of ammonia (δ 0.0 ppm).  
* Could not be determined due to lack of 1H-15N long-range correlation signal. 
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Supplementary 3. Inhibitory effects of deazapurine derivatives of L-ascorbic (1−4, 8−10, 
13−16) and imino-L-ascorbic acid (5−7, 12, 14−19) on the growth of malignant cell lines 
(HeLa, SW620, L1210/0, CEM/0, MiaPaCa-2, HepG2 and compound 9 on CFPAC-1) and 
cytotoxic effects on normal murine fibroblasts (3T3). 
 
Comp. 
IC50a 
HeLa SW620 L1210/0 CEM/0 MiaPaCa-2 HepG2 3T3 
1 15 ± 0 32.9± 0.1 6.8 ± 0.1 5.7 ± 1.4 22.6 ± 0.1 46.9 ± 0.4 26.4 ± 0.1 
2 >100 55 ± 0.1 n. d. n. d. 78 ± 0.01 >100 86 ± 0.1 
3 >100 50 ± 0.1 n. d. n. d. >100 >100 >100 
4 >100 >100 n. d. n. d. >100 >100 >100 
5 21 ± 0.1 >100 n. d. n. d. 60 ± 0.1 >100 58 ± 0.1 
6 77 ± 6 >100 50 ± 22 25 ± 4 48.7 ± 0.1 66.5 ± 0.1 33.0 ± 0.1 
7 39 59 ± 0.1 n. d. n. d. >100 >100 24 ± 0.07 
8 >100 >100 n. d. n. d. >100 >100 89 ± 0.3 
9 17 ± 0 >100 15 ± 0 12 ± 5 >100* >100 >100 
10 65 ± 3 >100 128 ± 66 ≥250 33.3 ± 0.1 >100 >100 
12 ≥250 46.9 ± 0.22 >250 >250 22.6 ± 0.1 32.4 ± 0.1 29.8 ± 0.1 
13 12 ± 4 47.1 ± 0.1 4.7 ± 0.1 4.1 ± 1.8 33.9 ± 0.1 >100 >100 
14 27 ± 1 >100 28 ± 5 16 ± 2 >100 >100 >100 
15 5.6 ± 1.3 47.2 ± 0.1 4.5 ± 0.5 19 ± 12 26.2 ± 0.1 >100 >100 
16 62 ± 12 56.8 ± 0.1 68 ± 14 32 ± 6 36.5 ± 0.1 >100 36.4 ± 0.1 
17 92 ± 3 90.7 ± 0.1 107 ± 6 87 ± 0 36.6 ± 0.2 >100 >100 
18 17 ± 2 69.9 ± 0.1 4.4 ± 0.3 15 ± 4 5.7 ± 0.2 >100 >100 
19 18 ± 2 30.5 ± 0.2 7.6 ± 3.8 4.9 ± 0.3 4.4 ± 0.1 52 ± 0.1 63.5 ± 0.1 
*Tested on pancreatic adenocarcinoma cells, CFPAC-1. 
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